Post-Acute Covid: An Update

COVID19 - CORONAVIRUS, 3 May 2021

Swiss Policy Research - TRANSCEND Media Service

“Long Covid”: Reduced lung perfusion in a young woman one year after “mild” covid. (Source: Marta Esperti)

Note: Patients are asked to consult a doctor.

29 Apr 2021 – In July/August 2020, SPR published one of the first fully fact-based analyses of post-acute covid (“long covid”), emphasizing that this condition may affect even young and healthy people who experienced only “mild” covid without hospitalization.

The etiology of this condition has remained rather mysterious, but recent findings by British experts indicate that even a “mild” coronavirus infection may induce micro-thrombosis and endotheliitis (micro blood clots and blood vessel inflammation) in the lungs, which may significantly impact perfusion and gas exchange, thus explaining why even some 35-year-old marathon runners can hardly climb stairs anymore.

Of note, this condition is not visible in standard x-ray and CT scans, but only in specialized lung perfusion and gas exchange scans. British lung specialists are currently trying to treat this condition with anti-coagulation (to dissolve any micro blood clots), apparently with some success. Additional studies are being planned.

This condition may well form the core of the “post-covid syndrome”, although some patients may experience additional neurological or other symptoms. In countries with an average age of covid deaths above 80 years, post-covid disabilities in previously healthy people may likely be the biggest public health impact of the pandemic, affecting up to 10% of infected people to some extent.

The risk of serious post-covid sequelae could justify covid vaccinations even in young and healthy adults (who do not belong to the actual covid risk group), although they should be aware of the risk of “rare”, but potentially serious or fatal vaccine adverse events, as well as the unknown long-term safety and effectiveness of these vaccines, in order to make an informed decision, especially since recent research indicates that the coronavirus spike protein alone, which is injected or induced by covid vaccines, can cause covid-like vascular damage in the lungs and other organs.

Furthermore, the post-covid issue once again highlights the importance of early treatment protocols, including the potential effectiveness of early anti-platelet and anti-coagulation treatment. Dr Erika Mendoza, secretary general of the German Medical Society of Venologists, emphasized this point in a recent talk, critizing that new regulatory requirements mean that a simple placebo-controlled trial of low-cost and safe aspirin against covid would cost more than 2 million euros.

See also:

‘Long Covid has destroyed me but I am fighting back’ (BBC, April 2021)

__________________________________________

Swiss Policy Research, founded in 2016, is an independent, nonpartisan and nonprofit research group investigating geopolitical propaganda in Swiss and international media. SPR is composed of independent academics that for personal and professional reasons prefer to protect their identities, and receives no external funding; there are no financial sponsors or backers. Our articles have been published or shared by numerous independent media outlets and journalists, among them Julian Assange, and have been translated into more than two dozen languages.

Go to Original – swprs.org


Tags: , , , , ,

 

Share this article:


DISCLAIMER: The statements, views and opinions expressed in pieces republished here are solely those of the authors and do not necessarily represent those of TMS. In accordance with title 17 U.S.C. section 107, this material is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes. TMS has no affiliation whatsoever with the originator of this article nor is TMS endorsed or sponsored by the originator. “GO TO ORIGINAL” links are provided as a convenience to our readers and allow for verification of authenticity. However, as originating pages are often updated by their originating host sites, the versions posted may not match the versions our readers view when clicking the “GO TO ORIGINAL” links. This site contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available in our efforts to advance understanding of environmental, political, human rights, economic, democracy, scientific, and social justice issues, etc. We believe this constitutes a ‘fair use’ of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, the material on this site is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes. For more information go to: http://www.law.cornell.edu/uscode/17/107.shtml. If you wish to use copyrighted material from this site for purposes of your own that go beyond ‘fair use’, you must obtain permission from the copyright owner.


There are no comments so far.

Join the discussion!

We welcome debate and dissent, but personal — ad hominem — attacks (on authors, other users or any individual), abuse and defamatory language will not be tolerated. Nor will we tolerate attempts to deliberately disrupt discussions. We aim to maintain an inviting space to focus on intelligent interactions and debates.

*

code

This site uses Akismet to reduce spam. Learn how your comment data is processed.